Head-to-head evidence
HLX04 vs LY01008
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: VEGF-A · full Non-Small Cell Lung Cancer pipeline
HLX04
Developed by Shanghai Henlius Biotech
NCT03952403 · Phase 3 · status unknown
Registry results were not posted at the time of grading; the key result shown was recovered from the cited external source.
The first listed primary outcome for this study is Part 1 safety and tolerability; the survival figures shown here are the Part 2 primary endpoint (progression-free survival) and the overall-survival secondary endpoint from the final analysis.
LY01008
Developed by Luye Pharma Group
NCT03533127 · Phase 3 · status unknown
This was a randomized, double-blind, active-controlled equivalence trial in 648 patients that measured objective tumor response rate, using the same paclitaxel/carboplatin backbone in both arms. LY01008's response rate was statistically equivalent to bevacizumab's, within the prespecified margin, meeting the trial's own equivalence criterion.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: HLX04's landscape · LY01008's landscape